Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.
|Year of publication||2005|
|Type||Article in Periodical|
|Magazine / Source||The hematology journal|
|MU Faculty or unit|
|Field||Oncology and hematology|
|Keywords||multiple myeloma; hypertension; angiotensin-1-converting enzyme|
|Description||In a retrospective study we have sought to determine whether the administration of angiotensin-I-converting enzyme inhibitors (ACEI) influences the outcome of patients with multiple myeloma (MM). Patients with MM who underwent autologous peripheral blood stem cell transplantation (PBSCT) (n=168) were studied. Patients taking ACEI alone or in combination with other antihypertensive agents during the hospital admission for PBSCT were allocated to the ACEI group (n=25; 15%). In conclusion, according to our findings, ACEI administered during PBSCT have adverse effect on survival of patients with MM.|